Trial Profile
ANTICANCER THERAPEUTIC VACCINATION USING TELOMERASE-DERIVED UNIVERSAL CANCER PEPTIDES IN METASTATIC NON SMALL CELL LUNG CANCER : A Phase I/II Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 28 Sep 2022
Price :
$35
*
At a glance
- Drugs HTERT peptide vaccine-Invectys (Primary) ; Montanide ISA-51
- Indications Adenocarcinoma; Large cell carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; First in man; Pharmacodynamics
- 07 Sep 2022 Results reporting safety, immunogenicity, and one year efficacy of universal cancer peptide-based vaccine published in the Journal of Clinical Oncology
- 10 May 2022 Planned End Date changed from 1 Jun 2022 to 20 Dec 2023.
- 10 May 2022 Planned primary completion date changed from 1 Sep 2021 to 30 May 2022.